Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy

Area of Science:

• Oncology
• Biotechnology
• Gene Therapy

Background:

• Continuous administration of angiogenesis inhibitors enhances antitumoral efficacy compared to intermittent dosing.
• Gene therapy presents a potential strategy for antiangiogenic tumor treatment.

Purpose of the Study:

• To establish a tissue-engineered implant for continuous in vivo production of thrombospondin-2 (TSP-2).
• To evaluate the therapeutic efficacy of TSP-2 gene therapy in inhibiting tumor growth and angiogenesis.

Main Methods:

• Fibroblasts were genetically modified to overexpress TSP-2 using retroviral transduction.
• Modified fibroblasts were seeded onto biodegradable polymer scaffolds to create bioimplants.
• Bioimplants were transplanted into nude mice, and TSP-2 secretion and its effects on distant tumors were assessed.

Main Results:

• Bioimplants demonstrated sustained high levels of TSP-2 secretion in vivo.
• Increased circulating TSP-2 levels were observed following bioimplant transplantation.
• Systemic TSP-2 effectively inhibited tumor growth and angiogenesis in various cancer models.

Conclusions:

• This study provides the first proof-of-principle for systemic, cell-based antiangiogenic gene therapy.
• Biodegradable polymer grafts are feasible for continuous TSP-2 production and cancer treatment.
• Tissue-engineered implants offer a promising strategy for sustained antiangiogenic gene therapy.